We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.12B
AUM Growth
+$199M
Cap. Flow
+$144M
Cap. Flow %
12.84%
Top 10 Hldgs %
31%
Holding
95
New
1
Increased
36
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.1M
2
LLY icon
Eli Lilly
LLY
+$9.29M
3
MDT icon
Medtronic
MDT
+$9.04M
4
CI icon
Cigna
CI
+$7.04M
5
ELV icon
Elevance Health
ELV
+$6.73M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$12.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.59M
3
BMY icon
Bristol-Myers Squibb
BMY
+$5.42M
4
AIMT
Aimmune Therapeutics
AIMT
+$4.76M
5
OMCL icon
Omnicell
OMCL
+$4.24M

Sector Composition

Rank Sector Weight
1 Healthcare 94.2%
2 Communication Services 2.08%
3 Industrials 0.52%
4 Technology 0.02%
5 Energy 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$11.6B
$56.6M 5.04%
744,354
+554,354
+292% +$56.1M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$54M 4.8%
695,000
-55,000
-7% -$3.78M
NVCR icon
3
NovoCure
NVCR
$1.73B
$45.6M 4.05%
409,600
+34,600
+9% +$2.77M
UNH icon
4
UnitedHealth
UNH
$376B
$34.3M 3.05%
110,000
+5,000
+5% +$1.54M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$121B
$29.9M 2.66%
110,000
-27,500
-20% -$7.59M
GH icon
6
Guardant Health
GH
$21.7B
$26.8M 2.39%
240,000
+55,000
+30% +$5.03M
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$25.9M 2.3%
190,000
+30,000
+19% +$3.19M
CI icon
8
Cigna
CI
$73.7B
$25.4M 2.26%
150,000
+40,000
+36% +$7.04M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$25.2M 2.24%
220,000
+30,000
+16% +$3.24M
HUM icon
10
Humana
HUM
$43.7B
$24.8M 2.21%
60,000
+5,000
+9% +$2.01M
ABBV icon
11
AbbVie
ABBV
$443B
$24.5M 2.18%
280,000
-20,000
-7% -$1.88M
LLY icon
12
Eli Lilly
LLY
$1.02T
$24.4M 2.17%
165,000
+60,000
+57% +$9.29M
JAZZ icon
13
Jazz Pharmaceuticals
JAZZ
$15.9B
$24.2M 2.16%
170,000
+32,968
+24% +$4.09M
ELV icon
14
Elevance Health
ELV
$81.5B
$24.2M 2.15%
90,000
+25,000
+38% +$6.73M
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
$23.5M 2.09%
460,000
-10,000
-2% -$417K
LVGO
16
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$23.4M 2.08%
166,961
+41,961
+34% +$5.11M
MDT icon
17
Medtronic
MDT
$109B
$22.9M 2.04%
220,780
+90,000
+69% +$9.04M
ABT icon
18
Abbott
ABT
$183B
$22.3M 1.98%
205,000
+20,000
+11% +$2.03M
COO icon
19
Cooper Companies
COO
$14.1B
$20.2M 1.8%
240,000
+80,000
+50% +$6.14M
BHVN
20
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$20.2M 1.79%
310,000
+100,000
+48% +$6.55M
ABMD
21
DELISTED
Abiomed Inc
ABMD
$19.4M 1.72%
70,000
+2,000
+3% +$576K
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$19M 1.69%
114,311
+14,311
+14% +$1.96M
IMMU
23
DELISTED
Immunomedics Inc
IMMU
$18.8M 1.67%
221,351
-238,649
-52% -$12.1M
GILD icon
24
Gilead Sciences
GILD
$162B
$18.3M 1.63%
290,000
+60,000
+26% +$4.16M
CNC icon
25
Centene
CNC
$30.7B
$17.5M 1.56%
300,000
+65,622
+28% +$4.08M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Rhenman & Partners Asset Management held 95 positions worth $1.12B, up 22% from $926M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $144M of net new capital in Q3 2020, opening 1 new position and adding to 36 existing holdings. Its largest new stake was Accolade Inc: 151,674 shares worth $5.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Communication Services and Industrials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $12.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2020 buy was Accolade Inc: 151,674 shares worth $5.9M.
  • Rhenman & Partners Asset Management added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $56.1M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $12.1M.
  • Rhenman & Partners Asset Management fully exited Aimmune Therapeutics in Q3 2020, selling an estimated $4.76M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.12B portfolio in Q3 2020.
  • Rhenman & Partners Asset Management opened 1 new position and closed 13 in Q3 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 22% quarter-over-quarter to $1.12B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2020, filed 13 Oct 2020.